BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 21, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

In the clinic for Sept. 17, 2021

Sep. 17, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Clene, Elucida, Gritstone, Rottapharm, Takis.
Read More

To boost or not to boost – the saga continues

Sep. 16, 2021
By Mari Serebrov
As members of the White House COVID-19 Response Team talk about COVID-19 boosters as if they are a fait accompli for Americans even before the FDA completes its evaluation of the data, the controversy continues to roil around the need for another vaccine dose.
Read More

Other news to note for Sept. 16, 2021

Sep. 16, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acino, ADQ, Aegis, Amgen, Bayer, Biocorp, Biozeus, Boehringer, Bold, Bwxt, Claritas, Clarus, Coave, Ellipses, Endeavor, Enterome, Exavir, Institute of Cancer Research, McGill, Merck, Oragenics, Oxitope, Phillip Morris, Quralis, Qure, Rakovina, Rapid Dose, RDIF, Remedium, Replicel, Resonant, Salk, Sanford Burnham, Soligenix, Strongbridge, Supertrans, Takeda, Taysha, Théa, Travere, Vifor, Vigil, Xeris.
Read More

In the clinic for Sept. 16, 2021

Sep. 16, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, Abivax, Acacia, Actinium, Aerie, Alx, Ampio, Arca, Axsome, Bayer, Biogen, Biophytis, Coherus, Crinetics, Daiichi, Eupraxia, Gammadelta, Gensight, Kinaset, Lineage, Monopar, Oramed, SAB, Seres, Theravance, Xilio.
Read More
Drug research

Drug developers up by 10%, but without Moderna, index fails to inspire

Sep. 15, 2021
By Karen Carey
Continuing an upward trajectory, BioWorld’s Drug Developers Index (BDDI) has climbed more than 10% since the start of this year, following sharp drops at the end of March and May. Shares began to rebound in June and the index has shown a steady incline, similar with the Nasdaq Biotechnology Index, which is currently up 12%.
Read More
Syringe and COVID-19 vaccine vials as question mark

Questions about COVID-19 boosters bigger than adcom

Sep. 15, 2021
By Mari Serebrov
The Biden administration’s haste to roll out an eight-month COVID-19 vaccine booster program next week is bumping up against the reality of the data and the regulatory process.
Read More

U.S. builds supply of Regeneron, Lilly COVID-19 antibody cocktails

Sep. 15, 2021
By Michael Fitzhugh
With the U.S. logging more than 4 million new COVID-19 cases in the past few weeks, federal purchasing of antibody cocktails from Regeneron Pharmaceuticals Inc. and Eli Lilly and Co. is continuing to grow. The government has placed orders for $2.94 billion worth of Regeneron's REGEN-COV (casirivimab and imdevimab) and about $330 million of Lilly's etesevimab to complement doses of bamlanivimab it previously purchased. Both antibody combinations, approved under FDA emergency use authorizations (EUAs), have been shown to reduce risk of hospitalization or death from COVID-19.
Read More

Other news to note for Sept. 15, 2021

Sep. 15, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abcellera, Biosplice, Cantex, Chimerix, Fate, Gilead, Glenmark, Haisco, Hookipa, Intelgenx, M8, Merck, Mindset, Moderna, Nanoscope, Nanoviricides, Nimble, Nuvectis, Orchard, Sanofi, Seneca, Translate, Vipergen.
Read More

In the clinic for Sept. 15, 2021

Sep. 15, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Astellas, Beckley Psytech, Calcimedica, Cstone, Emalex, Enzychem, Eqrx, Intrabio, Janssen, Jemincare, KSQ, Medicenna, Nimbus, NLS, Perception Neuroscience, Pharming, Redhill, Rocket, Valneva.
Read More
Deal handshake with graphic overlay

Everest adds mRNA candidates to pipeline in deals with Providence worth $500M+

Sep. 14, 2021
By Doris Yu
In a couple of deals worth more than $500 million, Everest Medicines Ltd. is picking up Asian rights to Providence Therapeutics Holdings Inc.’s mRNA candidates, including rights to a mRNA COVID-19 vaccine candidate currently in phase II testing.
Read More
Previous 1 2 … 187 188 189 190 191 192 193 194 195 … 552 553 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • Illustration of glucose in the blood stream

    CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

    BioWorld Science
    Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing